Introduction
Osteosarcoma (OS) is the most common type of primary malignant tumor of the bone in young adolescents and children. 1 The prognosis of patients with localized OS has been improved by the current treatment strategies, including preoperative chemotherapy, surgical resection and postoperative chemotherapy. 2 However, the use of adjuvant chemotherapy provides no survival advantage for patients with pulmonary metastases, whereas pulmonary metastasis is the leading cause of mortality in patients with OS. 3 Therefore, it is of particular importance to develop new molecular targets for the management of OS.
MicroRNAs (miRNAs) are a class of noncoding single-stranded RNA molecules encoded by endogenous genes with the length of about 22 nucleotides, which are involved in the regulation of posttranscriptional gene expression in plants and animals.
Up to now, over 15,000 miRNA gene loci in over 140 species and over 17,000 distinct mature miRNA sequences have been found. 4 Deep-sequencing technologies have delivered a sharp rise in the rate of novel miRNA discovery. Substantial studies have revealed that miRNAs are involved in the development and progression of cancers, acting as tumor suppressors or oncogenes by modulating gene expression. [5] [6] [7] [8] [9] Let-7 was first identified in Caenorhabditis elegans as a heterochronic gene. 10 The let-7 cluster was found to be dysregulated in various malignant tumors, and let-7 can prevent the malignant phenotype via the downregulation of oncogenes such as zinc finger-1, 11 high mobility group AT-Hook 2 (HMGA2) 12 and LIN2. 13 Let-7a is one of the members of let-7 family. Previous studies found that let-7a, as a tumor suppressor, plays an important role in the development of tumors by targeting oncogene cancer in several tumors. [14] [15] [16] Aurora-B (AURKB) is a component of chromosome passenger complex (CPC), which is composed of additional three activation regulators such as INCEP, survivin and borealin. AURKB plays important biological functions in regulating chromosome condensation and spindle assembly checkpoint (SAC), rectifying the faulty attachment between spindle and kinetochore, maintaining the correct chromosome alignment and the faithful chromosomal segregation. Accumulating evidence has shown that AURKB was highly expressed in various malignant tumors and as an important antitumor target. [17] [18] [19] [20] Our previous study indicated that AURKB showed increased expression in OS and the knockdown of AURKB inhibited proliferation, migration and invasion of OS cells in vitro. 21, 22 Although several miRNAs have been found to target AURKB, including let-7b 23 and miRNA-378a-5p, 24 the correlation of AURKB expression and let-7a in OS cells is still unclear.
In the current study, we found that the expression of let-7a was decreased, whereas that of AURKB was increased in OS tissues and cell lines compared with the normal bone tissues and hFOB1.19. Based on the inverse correlation between let-7a and AURKB expression in OS, we speculated that the elevated expression of AURKB in OS may be mediated, at least partially, by let-7a. We aimed to assess the effects of let-7a on OS progress and to determine whether the let-7a regulated AURKB expression in OS.
Patients and methods

Patients and clinical samples
Twenty-one specimens of OS were obtained by excision biopsy from patients with histologically proven OS of the extremities treated at the First Affiliated Hospital of Nanchang University and the Cancer Hospital of Jiangxi Province (Nanchang, People's Republic of China) between 2009 and 2012. The tissues obtained from an area 5 cm from the tumor margin were accounted as negative controls. No patient had a history of prior therapies with anticancer drugs or radiotherapy. The samples were stored in the -80°C fridge before quantitative PCR (qPCR) detection. The pathological diagnosis was confirmed by two practiced pathologists. All research methods were approved by the medical ethics committee of the First Affiliated Hospital of Nanchang University and followed the Declaration of Helsinki. All subjects were notified about the objectives, contents, latent risks and signed informed consents.
Cell culture and transfection
The U2-OS and 143B cell lines and the human osteoblast cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were routinely cultured in DMEM (Hyclone, Logan, UT, USA) supplemented with 10% FBS (Sigma-Aldrich Co., St Louis, MO, USA). Cells were cultured at 37°C in 5% CO 2 . The let-7a mimic, let-7a inhibitor and negative mimic were produced by Yingqi Biotechnology Company (Wuhan, People's Republic of China). Lipofectamine 2000 reagent (Thermo Fisher Scientific, Waltham, MA, USA) was used to transfect cells with let-7a mimics, let-7a inhibitor and negative mimic. The lentivirus vectors were compound by GeneChem Co. (Shanghai, People's Republic of China). U2-OS and 143B cells were transfected with lentivirus vectors of upregulating AURKB (Lv-AURKB) and negative lentivirus vectors (NC-AURKB), respectively. Infection/transfection process was operated according to the manufacturer's instructions.
Biological information prediction
Prediction of the AURKB 3¢-UTR as a miRNA-binding target was determined using TargetScan (www.targetscan. org), mirDIP (http://ophid.utoronto.ca) and starBase (http:// starbase.sysu.edu.cn).
luciferase reporter assay
To investigate whether let-7a could target AURKB directly, the luciferase reporter assay was performed as described in our previous study. 25 Reverse transcription quantitative realtime PCR (RT-qPCR)
The RNA was extracted from fresh OS tissues, adjacent nontumor tissues, OS cells and hFOB1.19 cells using the Qiagen RN easy FFPE protocol (Qiagen NV, Venlo, the Netherlands). 
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let-7a inhibits malignant phenotype of osteosarcoma cells les, CA, USA), and U6 snRNA and GAPDH were used as endogenous references. Total RNA in OS cells or tissues was extracted using TRIzol (Thermo Fisher Scientific). Reverse transcription was performed using Prime Script RT Reagent Kit (Takara Bio, Inc., Otsu, Japan) according to the manufacturer's protocol. Then, each sample was analyzed by qPCR under the conditions described in the manufacturer's instructions for SYBR Premix Ex Tap II (Thermo Fisher Scientific): 50°C for 2 minutes, 95°C for 2 minutes, followed by 40 cycles at 95°C for 15 seconds and 60°C for 30 seconds. Relative expression was calculated using the 2-ΔΔCt method. All of primer sequences are summarized in Table 1 .
Western blot analysis
Total protein was extracted using radioimmunoprecipitation lysis buffer (Beyotime Institute of Biotechnology) containing 60 µg/mL PMSF (Solarbio, Beijing, People's Republic of China). Protein concentration was determined by a Bradford assay (Bio-Rad Laboratories Inc.). Western blot analysis was conducted as described in the study by He et al. 26 Three independent experiments were performed over multiple days.
Cell Counting Kit-8 (CCK-8) assays
The proliferation of OS cells was evaluated using CCK-8. OS cells (4,000/well) were seeded per well in a 96-well plate and to grow for 24 hours. Then, 24 hours and 48 hours after transfection or infection, 10 µL CCK-8 solution was added to wells and incubated for 12 hours at 37°C. The absorbance of each well at 450 nm with microplate reader was measured. Three independent experiments were performed over multiple days.
Wound-healing assays
In brief, cells were grown to confluence in six-well tissue culture plastic dishes to a density of approximately 5×10 6 cells/well. The cells were denuded by dragging a rubber policeman (Thermo Fisher Scientific) through the center of the plate. Cell culture dishes were rinsed with PBS. Then, we added fresh quiescent medium alone or containing 10% FBS into the dishes and put the dishes into the incubator (37°C for 24 hours). Images were captured at 0 hour and 24 hours using an ECLIPSE-TS-100 microscope (magnification, ×200; Nikon Corporation, Tokyo, Japan), and the migrated distance was measured by Image J, version 1.48 (National Center for Biotechnology Information, Bethesda, MD, USA). The migration rates of cells were obtained by counting three fields per area and represented as the average of three independent experiments done over multiple days.
Transwell invasion assays
We used the BD BioCoatTM BD MatrigelTM Invasion Chamber (BD, Franklin Lakes, NJ, USA) to analyze the cell's invasion ability according to the specification. The medium in the lower chamber contained 5% fetal calf serum as a source of chemoattractants. Cells were suspended in serum-free medium and added to the upper chambers at the same time. Cells that passed through the Matrigel-coated membrane were stained with Diff-Quik (Sysmex, Kobe, Japan) and photographed (magnification, ×400). Images were captured at 24 hours, and cell counting was measured by Image J software. The values for invasion were obtained by counting three fields per membrane and represented as the average of three independent experiments conducted over multiple days.
in vivo tumor-bearing nude mice model
The athymic nude BALB/c mice (weight, 15±2 g; age, 6±2 weeks) were provided by the Department of Laboratory Animal Science of Nanchang University (Nanchang, People's Republic of China). The experimental model was established by injecting 1×10 7 cells, suspended in 200 µL PBS, in the proximal tibia bone marrow cavity of nude mice. Following 14 days, mice were randomly divided into three groups (n=12): 
Abbreviation: aURKB, aurora-B.
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Yu et al 1) injected with let-7a mimic; 2) injected with let-7a inhibitor and 3) injected with negative mimic. Using the Entranster TM in vivo kit (Engreen Biosystem Co., Ltd., People's Republic of China), 0.2 mL of let-7a mimic, let-7a inhibitor and negative mimic was intratumorally injected three times every other day, respectively. The mice were sacrificed at 6 weeks after injection. The volume and weight of the tumors were evaluated. Tumor volumes were calculated using the following formula: V (mm 3 ) = length × width 2 /2. The lung metastasis was measured by counting the metastatic node of OS cells using H&E staining. All animal experiments were approved by the human ethical review committee of the Nanchang University, Jiangxi, People's Republic of China, and performed according to the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals (1996).
statistical analyses
All measurement data were presented as mean ± SD. Student's t-test was used in two-sample analysis, and one-way ANOVA was used in multiple sample analysis. P<0.05 was considered to indicate a statistically significant difference. The Pearson correlation was used to evaluate the relationship between let-7a and AURKB in OS tissues. All analyses were performed using SPSS statistical software, version 13.0 (IBM Corporation, Armonk, NY, USA).
Results
negative relationship between let-7a and aURKB in Os tissues and cell lines
The result of biological information prediction showed that the AURKB 3¢-UTR is a let-7a binding target as shown in Figure  1A . To investigate the expression level of let-7a in OS tissues and cell lines (U2-OS, 143B, HOS and MG63), qRT-PCR was performed. The results revealed that the expression level of let-7a was significantly lower in OS tissues and cells than that in normal bone tissues and hFOB1.19 cells ( Figure 1B ). In addition, the upregulated expression of AURKB was found in OS tissues and cell lines (U2-OS, 143B, HOS and MG63) when compared with normal bone tissues and hFOB1.19 cells ( Figure 1C ). The Pearson correlation assay showed that there was a negative relationship between let-7a and AURKB in OS tissues ( Figure 1D ). These results suggested that a potential relationship may exist between let-7a and AURKB in OS.
let-7a negatively regulates aURKB expression in Os cells
We performed the biological information prediction and luciferase reporter assay to investigate whether AURKB is one of the potential targets of let-7a. The results showed that let-7a has predictive binding sites in the 3¢-UTR of AURKB and let-7a restrained the relative luciferase activity in the wildtype 3¢-UTR of AURKB as shown in our previous study. 25 The paired sequence between let-7a and AURKB mRNA 3¢-UTR is shown in Figure 2A . qRT-PCR was performed to evaluate the overexpression level of let-7a ( Figure 2B ). In addition, the protein and mRNA expression of AURKB were significantly lower in cells treated with let-7a mimic than those in cells treated with negative mimic. In addition, the protein and mRNA expression of AURKB were significantly higher in cells managed with let-7a inhibitor when compared with those cells treated with negative inhibitor (Figure 2C and D). These results indicated that let-7a could negatively regulate AURKB expression in OS cells.
ectogenous let-7a inhibits the malignant phenotype of Os cells by targeting aURKB
To explore the effect of let-7a on the proliferation, migration and invasion, OS cells were treated with let-7a mimic, let7a inhibitor and negative mimic, respectively. The ability of cell proliferation, migration and invasion was measured using CCK-8 and wound-healing and transwell invasion assays. The results showed that the viability, migratory and invasive ability was significantly lower in cells treated with let-7a mimic than those cells treated with let-7a inhibitor or negative mimic (Figure 3) . It indicated that let-7a has antimalignant phenotype effects in OS cells.
In addition, to investigate whether let-7a inhibits the malignant phenotype of OS cells by targeting AURKB, the OS cells were treated with let-7a mimic, let-7a inhibitor and Lv-AURKB combined with let-7a (coinfected). In Western blot assays, the results revealed that the AURKB protein level was significantly decreased in cells treated with let-7a mimic. However, partially downregulated AURKB protein level in co-transfected cells was observed (Figure 4) . The malignant phenotype of cells was investigated by measuring the proliferation, migration and invasion abilities. The data showed that the tumor inhibition of let-7a was partly rescued by upregulation of AURKB in OS cells (Figure 3) . It suggested that let-7a inhibits the malignant phenotype of OS cells at least partly by targeting AURKB in vitro.
let-7a decreased nF-κβ signaling pathway by targeting aURKB in Os cells 
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let-7a inhibits malignant phenotype of osteosarcoma cells mimic or inhibitor of let-7a. The protein of NF-κβ, MMP2 and MMP9 was measured using Western blot analysis. The results revealed that the expression levels of NF-κβp65, MMP2 and MMP9 proteins were significantly lower in cells treated with let-7a mimic than those in cells treated with negative mimic. While the NF-κβp65, MMP2 and MMP9 proteins were significantly higher in cells treated with let-7a inhibitor than those cells treated with negative mimic. It suggested that the upregulation of let-7a inhibits NF-κβ signaling pathway in OS cells, while the inhibiting effect was restored by the overexpression of AURKB (Figure 4 ). All the results indicated that let-7a decreased NF-κβ signaling pathway at least partly by targeting AURKB in OS cells.
let-7a expression inhibits Os cell growth and metastasis in vivo
To demonstrate the tumor inhibition of let-7a in OS, we established a xenograft model to investigate the effects of let-7a on tumor growth and metastasis. The results showed that growth and lung metastasis were significantly inhibited in the group treated with let-7a mimic than those treated with negative mimic, while the growth and lung metastasis were significantly promoted in the group treated with let-7a inhibitor when compared with the group treated with negative mimic (Table 2; Figure 5 ). These results indicated that let-7a has an effective activity to inhibit OS cell growth and lung metastasis in vivo. 
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Discussion
In the current study, we provided encouraging evidence in support of let-7a as a tumor suppressor via inhibiting NF-κβ/ MMP signaling by targeting AURKB in OS. AURKB is a component of CPC, which is composed of INCEP, survivin and borealin. AURKB mediates chromosome condensation by phosphorylating histone H3 on Ser10 and variant centrosome protein A (CENP-A) on Ser7. It is also involved in the regulation of SAC, rectifying the faulty attachment between spindle and kinetochore and maintaining the correct chromosome alignment and the faithful chromosomal segregation. Accumulated studies demonstrated that the activation of AURKB mediated phosphorylation of histone H2AX on Ser121, which in turn facilitates the autophosphorylation of AURKB. 27 During anaphase, AURKB via phosphorylating a series of downstream substrates, including mitotic kinesin-like protein 1 (MKLP1) and RacGAP1, 28 accelerated their deposition at mid-body and maintained the stabilization of central spindle. In addition, AURKB could lead to shortening of central spindle and promote cytokinesis via phosphorylation of Kif2A, the microtubule depolymerase. 29 Increasing studies revealed that AURKB was involved in malignant tumor cell growth and metastasis. [17] [18] [19] [20] In our previous studies, we found that AURKB was overexpressed in OS tissues and cells and the knockdown of AURKB by shRNA and small molecular inhibitor could inhibit the proliferation, migration and invasion abilities of OS cells in vitro. 21, 22 However, the molecular mechanism mediated AURKB overexpression in OS remains to be explored.
Several studies have shown that miRNAs act as cancer suppressors or oncogenes in OS. 30 ,31 miRNAs regulate cell growth, migration and metastasis via the regulation of its target gene. 32, 33 Considering the regulation of AURKB expression by miRNAs, we searched public databases described earlier for candidate miRNAs that targeted AURKB. Let-7 cluster was found in the databases. Numerous studies have identified members of the let-7 family to be suppressors of tumor cell proliferation. [11] [12] [13] There are 12 miRNAs in the let-7 cluster in human beings, including let-7a which has been confirmed to be decreased expression and closely related to the prognosis of patients with malignant tumor. [14] [15] [16] A previous study showed that let-7a was decreased expression in OS cell lines, and the upregulation of let-7a inhibits OS cell proliferation and metastasis. 34, 35 Accordingly, we investigated the expression of let-7a in OS tissues and cell lines. Consistent with the former study, the expression of let-7a was attenuated in tissues and OS cell lines when compared with adjacent normal bone tissues and hFOB1.19 cells. However, the accurate biological function and relative molecular mechanisms in OS are largely unknown. Target genes of let-7a include c-Myc, HMGA2, STAT3 and E2F2. [34] [35] [36] Although Liu et al 37 reported that let-7a regulates AURKB in endometrial carcinoma cells, the role of let-7a on AURKB expression in OS is still unclear. In addition to bioinformatical prediction, we performed a series of studies to investigate the target role of AURKB in OS, as transfection of let-7a caused a substantial reduction in luciferase activity by the luciferase expression constructs that carry the target AURKB fragment compared with the mutant constructs that lack the binding site to let-7a. Further, ectopic expression of let-7a significantly decreased the transcription and translation of the AURKB gene, namely, these results indicated that AURKB is a target of let-7a in OS cells.
In addition, we analyzed the effects of let-7a on the biological behaviors of OS cells. Similar to the study by Iwasaki et al, 35 we found that exogenous let-7a prevented OS cell proliferation, migration and invasion in vitro. To further elucidate whether let-7a alters malignant phenotype of OS cells via directly targeting AURKB in OS, the cells, treated with let-7a mimic, were transfected with lentivirus plasmid of overexpression of AURKB, and the malignant phenotype of cells was measured. The results showed that the tumor inhibition mediated by let-7a was partly restored by increasing AURKB. In addition, in this study, the upregulation of let-7a could suppress OS cell growth and lung metastasis in nude mice. These data suggested that let-7a alters the malignant phenotype of OS cells at least partly by targeting AURKB.
Looking downstream of AURKB activation, we investigated the effect of altering AURKB by let-7a mimic and inhibitor on NF-κβ signaling pathway. Most importantly, our previous studies have confirmed the role of the AURKB/NF-κβ signaling pathway in OS, and the knockdown of AURKB inhibits NF-κβ signaling pathway. is localized mainly to the cytoplasm in an inactive form bound to I-κB. Several studies showed that the activation of NF-κβ could promote MMP2 and MMP9 proteins. 38 Decreased expression of MMP-2 and MMP-9 promotes cell invasion and metastasis by degrading components of the basement membrane and epimatrix in malignant tumor. [39] [40] [41] [42] In this study, we found that let-7a inhibits the growth and metastasis of OS cells and decreases the expression of NF-κβ p65, MMP2 and MMP9 proteins. The abovementioned results indicated that the expression of let-7a was downregulated in OS patients and negatively correlated with that of AURKB, and let-7a inhibits OS cells and lung metastasis by targeting AURKB in vivo and in vitro. It is suggested that targeting let-7a/AURKB axis may be a therapeutic strategy for OS management. However, in view of the functions of AURKB, such as regulating chromosome condensation and SAC, rectifying the faulty attachment between spindle and kinetochore, maintaining the correct chromosome alignment and the faithful chromosomal segregation, clinical practice of targeting let-7a/AURKB axis may lead to side effects that are worthy of attention, such as dysregulation of mitotic mechanisms. In addition, whether let-7a/AURKB axis differs between patients with and without lung metastasis remains unexplored. Therefore, more further clinical studies are particularly important now.
Conclusion
Our findings demonstrate that let-7a is underexpressed in OS and acts as a tumor suppressor which inhibits the malignant phenotype of cells via decreased NF-κβ signaling pathway by targeting AURKB partially. Targeting let-7a and AURKB/ NF-κβ may be a therapeutic strategy for OS management.
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